Article

Treatment with Antitumor Agents Recommended by Cancer Genome Panel for Uterine Leiomyosarcoma

2023-10-23

Abstract excerpt

To date, cancer genomic medicine, using cancer gene panel covered by health insurance in June 2019, has been performed for advanced malignant tumors under public medical insurance. In gynecology, the first-line treatment for uterine leiomyosarcomas, which is a mesenchymal uterine tumor, is surgery. In uterine leiomyosarcoma cases, recurrence is observed within 2 years postoperatively; however, to date, clinical tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d4dcf5e6-25ee-53b6-bb54-9d24c5287cd5
DOI: 10.32388/1izc3v

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Treatment with Antitumor Agents Recommended by Cancer Genome Panel for Uterine LeiomyosarcomaDOI 10.32388/1izc3vRead

Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancerSemantic proximity Read

Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significanceSemantic proximity Read

A Deep Multi-Omics Integration Approach Reveals New Molecular Features of Uterine LeiomyosarcomaSemantic proximity Read

Genomic Database Analysis of Uterine Leiomyosarcoma Mutational ProfileSemantic proximity Read

Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.Semantic proximity Read

Efficacy of Antitumor Drugs Against Uterine Leiomyosarcoma Obtained Through the Analysis of LMP2-Deficient Mice and the Result from a Cancer Gene Panel at Cancer Genomic MedicineSemantic proximity Read

Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus LeiomyosarcomaSemantic proximity Read

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Semantic proximity Read

Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.Semantic proximity Read

Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.Semantic proximity Read

Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.Semantic proximity Read

[Management of Cancer Genomic Board and Preparation of Genomic Report].Semantic proximity Read